Alcántara-Aragón V. Improving patient self-care using diabetes technologies. Ther Adv Endocrinol Metab. 2019; 10

Alva S, Bailey T, Brazg R Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes. J Diabetes Sci Technol. 2022; 16:(1)70-77

Barnard-Kelly KD, Polonsky WH Development of a novel tool to support engagement with continuous glucose monitoring systems and optimize outcomes. J Diabetes Sci Technol. 2020; 14:(1)151-154

Battelino T, Danne T, Bergenstal RM Clinical Targets for continuous glucose monitoring data interpretation: recommendations from the international Consensus on Time in Range. Diabetes Care. 2019; 42:(8)1593-1603

Bilous RW, Donnelly R, Idris I Handbook of Diabetes, 5th Edition edn. London: John Wiley & Sons; 2021

Chehregosha H, Khamseh ME, Malek M, Hosseinpanah F, Ismail-Beigi F. A View Beyond HbA1c: Role of Continuous Glucose Monitoring. Diabetes Ther. 2019; 10:(3)853-863

Crabtree TSJ, Choudhary P, Kar P, Wilmot EG ‘Flash glucose monitoring: the story so far and the journey ahead’. BMJ Innovations. 2022;

Nathan DM, Genuth S The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:(14)977-986

DiMeglio LA, Evans-Molina C, Oram RA Type 1 diabetes. Lancet. 2018; 391:(10138)2449-2462

DSN Nurse Forum. Intermittent and real-time continuous glucose monitoring system comparison chart. 2022. (accessed 12 January 2023)

Driver and Vehicle Licensing Agency. A guide to insulin treated diabetes and driving. 2019. (accessed 13/12/22)

Edelman SV, Argento NB, Pettus J, Hirsch IB Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. Diabetes Care. 2018; 41:(11)2265-2274

Forlenza GP, Argento NB, Laffel LM Practical Considerations on the Use of Continuous Glucose Monitoring in Pediatrics and Older Adults and Nonadjunctive Use. Diabetes Technol Ther. 2017; 19:(S3)S13-S20

Holt TA, Kumar S, Watkins PJ ABC of diabetes, Seventh edition edn. Chichester, West Sussex: Wiley Blackwell/BMJ Books; 2015

Kato N, Cui J, Kato M Structured self-monitoring of blood glucose reduces glycated hemoglobin in insulin-treated diabetes. J Diabetes Investig. 2013; 4:(5)450-453

Leelarathna L, Wilmot EG Flash forward: a review of flash glucose monitoring. Diabet Med. 2018; 35:(4)472-482

Leelarathna L, Evans ML, Neupane S Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes. N Engl J Med. 2022; 387:(16)1477-1487

Lind M, Polonsky W, Hirsch IB continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017; 317:(4)379-387

Marks BE, Williams KM, Sherwood JS, Putman MS Practical aspects of diabetes technology use: Continuous glucose monitors, insulin pumps, and automated insulin delivery systems. J Clin Transl Endocrinol. 2022; 27

Messer LH, Johnson R, Driscoll KA, Jones J Best friend or spy: a qualitative meta-synthesis on the impact of continuous glucose monitoring on life with Type 1 diabetes. Diabet Med. 2018; 35:(4)409-418

Milne N. How to initiate and support continuous glucose monitoring. Diabetes & Primary Care. 2022; 24:139-41

National Institute for Health and Care Excellence. NICE guideline 17: Type 1 diabetes in adults: diagnosis and management. 2022. (accessed 12 January 2023)

Pickup JC, Ford Holloway M, Samsi K Real-time continuous glucose monitoring in type 1 diabetes: a qualitative framework analysis of patient narratives. Diabetes Care. 2015; 38:(4)544-550

Reddy N, Verma N, Dungan K Monitoring Technologies-Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control. In: Feingold KR, Anawalt B, Boyce A (eds). South Dartmouth (MA)2020

Teo E, Hassan N, Tam W, Koh S Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. Diabetologia. 2022; 65:(4)604-619

Yoo JH, Kim G, Lee HJ, Sim KH, Jin SM, Kim JH Effect of structured individualized education on continuous glucose monitoring use in poorly controlled patients with type 1 diabetes: A randomized controlled trial. Diabetes Res Clin Pract. 2022; 184

Wilmot EG, Lumb A, Hammond P Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic. Diabet Med. 2021; 38:(1)

Continuous glucose monitoring for type 1 diabetes

02 February 2023
Volume 34 · Issue 2


Continuous glucose monitoring (CGM) is now a standard of care technology, which enables people living with type 1 diabetes to quickly monitor and manage their glucose levels without frequent, painful, finger-prick testing. This article will provide an overview of CGM technologies, including the most common types of devices, the data generated and information regarding access to these devices via NHS funding, alongside guidance for CGM use in clinical practice. Diabetes technologies are developing at pace, and so practice nurses will increasingly encounter people using CGM.

Continuous glucose monitoring is now available to all those living with type 1 diabetes. Charlotte Gordon provides an overview of the technology for nurses working in general practice

Diabetes mellitus is a condition that results in elevated blood glucose levels (hyperglycaemia). Clinical signs and symptoms include polydipsia, polyuria, weight loss, fatigue, blurred vision and recurrent infections (Holt et al, 2015). Continued elevation of blood glucose contributes to progressive long-term micro- and macrovascular complications across multiple organ systems, potentially leading to renal, nerve and ocular damage, representing a significant contribution to morbidity and mortality (Bilous et al, 2021).

Type 1 diabetes mellitus (T1DM) represents approximately 8–10% of all cases of diabetes (Holt et al, 2015). The pathogenesis of T1DM is complex, principally arising from an autoimmune destruction of insulin-secreting beta cells within the pancreas (DiMeglio et al, 2018).

Optimal glycaemic management, defined as glucose concentrations which mimic those of people without diabetes (normoglycaemia), has long been noted as leading to a reduction in diabetes-related complications (Diabetes Control and Complications Trial Research Group et al, 1993). Frequent monitoring of blood glucose via finger prick testing has historically been established as key in achieving effective glycaemic ranges (Kato et al, 2013).

Register now to continue reading

Thank you for visiting Practice Nursing and reading some of our peer-reviewed resources for general practice nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month